CorMedix Inc.

Equities

CRMD

US21900C3088

Pharmaceuticals

Real-time Estimate Cboe BZX 10:20:37 2024-03-28 am EDT 5-day change 1st Jan Change
4.2 USD +0.96% Intraday chart for CorMedix Inc. +8.71% +12.76%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care Stocks Ease Wednesday Afternoon MT
CorMedix Remains Encouraged on DefenCath Opportunity, RBC Says MT
RBC Trims Price Target on CorMedix to $9 From $10, Keeps Outperform Rating, Speculative Risk Qualifier MT
Transcript : CorMedix Inc., Q4 2023 Earnings Call, Mar 12, 2024
CorMedix Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
CorMedix Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
North American Morning Briefing : Inflation Data -2- DJ
CorMedix Inc. Updates Related to Its Business and Anticipated Launch of DefenCath CI
Cormedix Inc. Announces Commercial and Operational Updates CI
CorMedix Inc. Approves the Separation of Employment of Phoebe Mounts CI
CorMedix Inc. Announces the Appointment of Beth Zelnick Kaufman, Esq. as Executive Vice President, Chief Legal Officer, and Corporate Secretary, Effective December 12, 2023 CI
CorMedix Inc. Announces Partnership with The Leapfrog Group CI
Sector Update: Health Care Stocks Mixed Late Afternoon MT
Sector Update: Health Care Stocks Mixed Wednesday Afternoon MT
Sector Update: Health Care MT
CorMedix Inc. Announces FDA Approval of DefenCath(R) to Reduce the Incidence of Catheter Related Bloodstream Infections in Adult Hemodialysis Patients CI
CorMedix's DefenCath Approved by US FDA; Shares Jump MT
U.S. FDA approves CorMedix's antimicrobial drug RE
RBC Boosts Price Target on CorMedix to $10 From $6 on 'Heightening Prospects of DefenCath Reaching Market,' Keeps Outperform, Speculative Risk MT
CorMedix Q3 Net Loss Steady; Sees Cash Position Sufficient to Fund Operations for 12 Months MT
Transcript : CorMedix Inc., Q3 2023 Earnings Call, Nov 14, 2023
CorMedix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
CorMedix Gets US Patent Covering Lead Product DefenCath MT
Cormedix Inc. Announces Resignation of Paulo F. Costa as Member of the Board of Directors, Effective as of October 15, 2023 CI
RBC Initiates CorMedix at Outperform, Speculative Risk With $6 Price Target, Sees DefenCath 'More Likely Than Not to Be Approved' MT
Chart CorMedix Inc.
More charts
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.16 USD
Average target price
13 USD
Spread / Average Target
+212.50%
Consensus
  1. Stock
  2. Equities
  3. Stock CorMedix Inc. - Nasdaq
  4. News CorMedix Inc.
  5. Earnings Flash (CRMD) CORMEDIX Posts Q3 Revenue $6,817